Glaukos (GKOS) Stock Jumps 3.7%: Will It Continue to Soar?

This glaucoma treatments developer is expected to post quarterly loss of $0.51 per share in its upcoming report, which represents a year-over-year change of +7.3%. Revenues are expected to be $88.41 million, up 10% from the year-ago quarter. Glaukos is a member of the Zacks Medical - Instruments industry. One other stock in the same industry, Teleflex (TFX) , finished the last trading session 0.7% higher at $200.03. TFX has returned -2.9% over the past month. Glaukos (GKOS) shares rallied 3.7% in the last t ...